Aclaris Therapeutics Inc
Research Aclaris Therapeutics Inc (ACRS) on Bullrun: market cap USD 701.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACRS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 701.11M
- Financial periodFY2025
- RevenueUSD 7.83M
- Revenue growth-58.2%
- Net income-USD 64.92M
- Free cash flow-USD 47.22M
- Gross margin73.3%
Valuation Snapshot
latest market cap is USD 701.11M.
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease;
Frequently asked questions
What is Aclaris Therapeutics Inc's market cap?
Aclaris Therapeutics Inc's market capitalization is USD 701.11M.
What does Aclaris Therapeutics Inc do?
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.